SequelSEC

Verrica Pharmaceuticals Inc. VRCA

Pharmaceutical Preparations · CIK 0001660334 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$5.86M
Fiscal year ended 2026-06-30
Operating income
-$13.10M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Verrica Pharmaceuticals Inc. (VRCA) reported revenue of $5.86M and net income of -$13.15M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Verrica Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Verrica Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$5.86M$5.02M$5.09M$14.34M$12.70M$3.44M$344.00K-$1.78M$5.18M$3.83M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable$700.00K$800.00K$400.00K$700.00K$700.00K
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$13.10M-$9.72M-$7.19M$1.63M$1.51M-$8.13M-$11.41M-$20.70M-$15.21M-$18.60M
Net income-$13.15M-$9.68M-$8.07M-$274.00K$204.00K-$9.74M-$16.20M-$22.86M-$17.19M-$20.33M
Research & development$6.03M$3.86M$2.52M$2.20M$1.85M$2.28M$1.17M$2.40M$3.32M$4.95M
Weighted-average diluted sharesshares 21.31Mshares 21.31MUnavailableshares 9.49Mshares 9.49Mshares 9.48MUnavailableshares 4.68Mshares 4.65Mshares 46.48M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.62$-0.45Unavailable$-0.03$0.02$-1.03Unavailable$-4.88$-3.70$-0.44
Selling, general & administrative$10.35M$9.99M$8.12M$9.40M$8.85M$8.85M$9.88M$16.08M$16.52M$16.34M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Verrica Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$11.20M$20.60M$30.15M$21.10M$15.40M$29.60M$46.33M$22.96M$31.93M$48.94M
Total assets$36.02M$38.79M$47.13M$40.90M$39.11M$42.18M$54.13M$32.93M$52.01M$66.31M
Current assets$32.64M$34.13M$42.54M$36.28M$36.78M$39.47M$51.18M$28.19M$47.32M$61.38M
Total liabilities$31.71M$22.73M$22.39M$57.94M$56.59M$60.75M$63.99M$66.98M$65.31M$64.80M
Current liabilities$22.44M$16.22M$16.44M$28.91M$29.22M$29.40M$29.01M$21.03M$20.05M$19.36M
Total equity incl. NCI$4.31M$16.06M$24.74M-$17.04M-$17.48M-$18.58M-$9.86M-$34.05M-$13.30M$1.51M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$2.71M$1.97M$2.24M$2.30M$2.52M$2.46M$2.46M$2.58M$2.70M$2.50M
Accounts receivable$10.94M$7.72M$5.26M$7.05M$9.19M$5.61M$48.00K$0$10.03M$7.00M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$0$21.62M$24.58M$27.81M$30.98M$43.30M$42.75M$42.85M
Accounts payable$1.60M$2.19M$2.07M$1.58M$2.32M$1.44M$1.90M$966.00K$1.15M$2.53M

Cash flow

Verrica Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$9.28M-$9.16M-$4.59M$9.68M-$10.04M-$12.68M-$16.06M-$8.56M-$16.36M-$19.95M
Capital expendituresUnavailableUnavailable$0$0UnavailableUnavailable$0$16.00K$11.00K$0
Investing cash flow$0$0$0$0$0$0$8.00K-$16.00K-$11.00K$0
Financing cash flow-$126.00K-$120.00K$13.64M-$3.98M-$4.16M-$4.06M$39.43M-$397.00K-$640.00K-$661.00K
Net change in cash-$9.40M-$9.28M$9.05M$5.70M-$14.20M-$16.73M$23.37M-$8.97M-$17.01M-$20.61M
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Verrica Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailable-$4.59M$9.68MUnavailableUnavailable-$16.06M-$8.57M-$16.37MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-223.4%-193.4%-141.2%11.3%11.9%-236.4%-3316.9%Unavailable-293.7%-486.1%
FCF marginUnavailableUnavailable-90.2%67.5%UnavailableUnavailable-4669.8%Unavailable-316.2%Unavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.45x2.10x2.59x1.25x1.26x1.34x1.76x1.34x2.36x3.17x
Revenue YoY growth-53.8%46.1%1380.2%Unavailable145.4%-10.1%-82.7%-161.1%2744.5%10240.5%
Net margin-224.4%Unavailable-158.6%-1.9%1.6%Unavailable-4709.9%UnavailableUnavailableUnavailable
R&D / revenue102.9%76.8%49.5%15.4%14.5%66.4%339.5%Unavailable64.1%129.3%
CapEx / revenueUnavailableUnavailable0.0%0.0%UnavailableUnavailable0.0%Unavailable0.2%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VRCA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

6 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.